Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Prognostic Factors Identified Via a Cox Proportional Hazard Cure Model Explain Survival Differences After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myeloid Leukemia (CML) Between Two Consecutive Patient Cohorts

Blood (2012) 120 (21): 3748.

https://doi.org/10.1182/blood.V120.21.3748.3748

Published: 2012

Journal Articles

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

Blood (2007) 109 (11): 4686–4692.

https://doi.org/10.1182/blood-2006-11-055186

Published: 2007

Includes: Supplemental data

Journal Articles

Transient Response to Imatinib in an Atypical Chronic Myeloproliferative Disease Associated with ins(9;4)(q34;q21q31) and a CDK5RAP2-PDGFRA Fusion Gene.

Christoph Walz, Beate Schultheis, Georgia Metzgeroth, Claudia Schoch, Claire Curtis, Eva Lengfelder, Torsten Haferlach, Ute Berger, Andreas Hochhaus, Rüdiger Hehlmann, Nicholas C.P. Cross, Andreas Reiter

Blood (2005) 106 (11): 3281.

https://doi.org/10.1182/blood.V106.11.3281.3281

Published: 2005

Journal Articles

Concept, Feasibility and Results of the Randomized Comparison of Imatinib Combination Therapies for Chronic Myeloid Leukemia: The German CML-Study IV.

Ute Berger, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Claudia Schoch, MD, Andreas Reiter, MD, Gerhard Ehninger, MD, Thomas Fischer, MD, Alois Gratwohl, MD, Joerg Hasford, MD, Hermann Heimpel, MD, Dieter K. Hossfeld, MD, Hans-J. Kolb, MD, Stefan Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Andreas Tobler, MD, Ruediger Hehlmann, MD, The German CML-Study Group

Blood (2005) 106 (11): 1083.

https://doi.org/10.1182/blood.V106.11.1083.1083

Published: 2005

Journal Articles

Early Detection of Imminent Hematologic Relapse Due to BCR-ABL Kinase Domain Mutations in CML Patients on Imatinib Therapy by D-HPLC.

Thomas Ernst, MD, Philipp Erben, MD, Thomas Schenk, MD, Martin C. Mueller, MD, Michael Emig, MD, Sebastian Kreil, MD, Paul La Rosée, MD, Ute Berger, MD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2005) 106 (11): 1088.

https://doi.org/10.1182/blood.V106.11.1088.1088

Published: 2005

Journal Articles

Feasibility of Imatinib Combination Therapies in a Randomized Trial for Chronic Myeloid Leukemia: The German CML-Study IV - Pilot Phase.

Ute Berger, MD, Andreas Hochhaus, MD, Andreas Reiter, MD, Markus Pfirrmann, Claudia Schoch, MD, Gerhard Ehninger, MD, Thomas Fischer, MD, Alois Gratwohl, MD, Joerg Hasford, MD, Hermann Heimpel, MD, Dieter K. Hossfeld, MD, Hans-J. Kolb, MD, Stefan Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Andreas Tobler, MD, Rüdiger Hehlmann, MD, the German CML-Study Group

Blood (2004) 104 (11): 24.

https://doi.org/10.1182/blood.V104.11.24.24

Published: 2004

Journal Articles

Recurrent Fusion of PCM1 to JAK2 in Atypical Chronic Myeloid Leukemia and Acute Leukemia Associated with the t(8;9)(p21-22;p23-24).

Andreas Reiter, Christoph Walz, Ann Watmore, Claudia Schoch, Ilona Blau, Nick Telford, Shilani Aruliah, John Yin, Danny Vanstraelen, Helen Barker, Peter Taylor, Aisling O’Driscoli, Brigitte Schlegelberger, Ute Berger, Andreas Hochhaus, Rüdiger Hehlmann, Andrew Chase, Nicholas C.P. Cross

Blood (2004) 104 (11): 2963.

https://doi.org/10.1182/blood.V104.11.2963.2963

Published: 2004

Journal Articles

PEG-Interferon for Chronic Phase CML - Still an Option in the Era of Imatinib?.

Christof Scheid, MD, Andreas Draube, MD, Udo Holtick, MD, Oliver Cornely, MD, Ulrich Hacker, MD, Michael Fuchs, MD, Ute Berger, MD, Andreas Hochhaus, MD, PhD, Rüdiger Hehlmann, MD, PhD, Michael Hallek, MD, PhD

Blood (2004) 104 (11): 4662.

https://doi.org/10.1182/blood.V104.11.4662.4662

Published: 2004

Journal Articles

Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia

Tim H. Brümmendorf, Inci Ersöz, Ulrike Hartmann, Kerol Bartolovic, Stefan Balabanov, Alexandra Wahl, Peter Paschka, Sebastian Kreil, Tanja Lahaye, Ute Berger, Harald Gschaidmeier, Carsten Bokemeyer, Rüdiger Hehlmann, Klaus Dietz, Peter M. Lansdorp, Lothar Kanz, Andreas Hochhaus

Blood (2003) 101 (1): 375.

https://doi.org/10.1182/blood-2002-08-2557

Published: 2003

Journal Articles

ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia

Josu de la Fuente, Kirsten Merx, E. Joanna Steer, Martin Müller, Richard M. Szydlo, Ole Maywald, Ute Berger, Rüdiger Hehlmann, John M. Goldman, Nicholas C. P. Cross, Junia V. Melo, Andreas Hochhaus, the German CML Study Group

Blood (2001) 98 (9): 2879–2880.

https://doi.org/10.1182/blood.V98.9.2879

Published: 2001

Journal Articles

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

Andreas Hochhaus, Andreas Reiter, Susanne Saußele, Anja Reichert, Michael Emig, Jaspal Kaeda, Beate Schultheis, Ute Berger, Patricia C. A. Shepherd, Norman C. Allan, Rüdiger Hehlmann, John M. Goldman, Nicholas C. P. Cross

Blood (2000) 95 (1): 62–66.

https://doi.org/10.1182/blood.V95.1.62

Published: 2000

Journal Articles

Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure

Blood (1999) 94 (11): 3668–3677.

https://doi.org/10.1182/blood.V94.11.3668

Published: 1999

NARROW

Prognostic Factors Identified Via a Cox Proportional Hazard Cure Model Explain Survival Differences After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myeloid Leukemia (CML) Between Two Consecutive Patient Cohorts

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

Transient Response to Imatinib in an Atypical Chronic Myeloproliferative Disease Associated with ins(9;4)(q34;q21q31) and a CDK5RAP2-PDGFRA Fusion Gene.

Concept, Feasibility and Results of the Randomized Comparison of Imatinib Combination Therapies for Chronic Myeloid Leukemia: The German CML-Study IV.

Early Detection of Imminent Hematologic Relapse Due to BCR-ABL Kinase Domain Mutations in CML Patients on Imatinib Therapy by D-HPLC.

Feasibility of Imatinib Combination Therapies in a Randomized Trial for Chronic Myeloid Leukemia: The German CML-Study IV - Pilot Phase.

Recurrent Fusion of PCM1 to JAK2 in Atypical Chronic Myeloid Leukemia and Acute Leukemia Associated with the t(8;9)(p21-22;p23-24).

PEG-Interferon for Chronic Phase CML - Still an Option in the Era of Imatinib?.

Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia

ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only